Description

The global drug discovery market is poised to grow by US$ 44.3 billion from 2022 to 2028, registering a CAGR of 8.7% during the forecast period, according to StrategyHelix.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for drug discovery. The global drug discovery market is segmented on the basis of type, drug type, disease application, end user, and region. By type, the global drug discovery market has been segmented into bioanalytical instruments, bioinformatics, cell-based assays and reagents, genomics, high-throughput screening, proteomics, others. The bioanalytical instruments segment was the largest contributor to the global drug discovery market in 2021. Based upon drug type, the global drug discovery market is categorized into biologics, small-molecule drugs. On the basis of disease application, the global drug discovery market has been segmented into cancer, cardiovascular, immunological, neurological, others. The cancer segment held the largest revenue share in 2021. By end user, the global drug discovery market has been segmented into academia and research institutes, contract research organizations (CROs), pharmaceutical companies. In terms of geography, the global drug discovery market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global drug discovery market is highly competitive. The competitive landscape of the industry has also been examined along with the profiles of the key players Agilent Technologies Inc., AMETEK Inc., Arrayit Corp., Becton Dickinson and Company, Biomax Informatics AG, Bio-Rad Laboratories Inc., Bruker Corp., Charles River Laboratories Inc., Danaher Corp., General Electric Company (GE), Hitachi High-Technologies Corporation, Illumina Inc., JEOL Ltd., LECO Corporation, Merck KGaA, Perkin Elmer Inc., Qiagen N.V., Roche Holding AG, Shimadzu Corporation, Thermo Fisher Scientific Inc.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the drug discovery market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: bioanalytical instruments, bioinformatics, cell-based assays and reagents, genomics, high-throughput screening, proteomics, others
Drug type: biologics, small-molecule drugs
Disease application: cancer, cardiovascular, immunological, neurological, others
End user: academia and research institutes, contract research organizations (CROs), pharmaceutical companies
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global drug discovery market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Drug discovery market overview
Part 3. Market breakdown by type
– Bioanalytical instruments
– Bioinformatics
– Cell-based assays and reagents
– Genomics
– High-throughput screening
– Proteomics
– Others
Part 4. Market breakdown by drug type
– Biologics
– Small-molecule drugs
Part 5. Market breakdown by disease application
– Cancer
– Cardiovascular
– Immunological
– Neurological
– Others
Part 6. Market breakdown by end user
– Academia and research institutes
– Contract research organizations (CROs)
– Pharmaceutical companies
Part 7. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 8. Key companies
– Agilent Technologies Inc.
– AMETEK, Inc.
– Arrayit Corp.
– Becton, Dickinson and Company
– Biomax Informatics AG
– Bio-Rad Laboratories, Inc.
– Bruker Corp.
– Charles River Laboratories, Inc.
– Danaher Corp.
– General Electric Company (GE)
– Hitachi High-Technologies Corporation
– Illumina, Inc.
– JEOL Ltd.
– LECO Corporation
– Merck KGaA
– Perkin Elmer Inc.
– Qiagen N.V.
– Roche Holding AG
– Shimadzu Corporation
– Thermo Fisher Scientific Inc.
About StrategyHelix
Disclaimer